venBio
Life-sciences investment firm founded in 2011, backing companies developing novel therapeutics and supporting them on development planning, regulatory strategy and acquisition readiness.
venBio is a life-sciences investment firm founded in 2011 that backs companies developing differentiated medicines, with a focus on novel therapeutics addressing unmet medical needs. The firm invests across stages of clinical development and works alongside portfolio teams on development planning rather than confining its role to capital provision. It has offices in San Francisco and Seattle, and describes its model as partnering with industry leaders to build medicines and technologies.
The firm's involvement spans the practical disciplines that determine whether a therapy reaches patients: intellectual property, chemistry and manufacturing (CMC), clinical trial design, clinical endpoints and regulatory strategy. Its stated objective is to help companies think through development plans that bring therapies to patients and to make a meaningful difference in patient care - a mandate that concentrates attention on therapeutic novelty rather than platform breadth alone.
A second strand of the model concerns exit positioning. venBio helps portfolio companies consider potential acquisition partners early in their development and prepare for the requirements those partners are likely to assess, including CMC and data packages. This orientation towards acquisition readiness, combined with hands-on work on development planning, characterises a firm whose operating involvement is designed to extend well beyond the point of investment.